PVLA Palvella Therapeutics, Inc. Common Stock
XNAS
175.00
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
PVLA
$175.00
—
What changed
Recent filings, trades and movesKey stats
$175.00
- 52-Week Range
- $72.22 – $179.95
- YTD
- +74.52%
- IV Rank (30D)
- 10.18
- Straddle Price
- $22.85
- P/C Vol Ratio
- 0.19
- Market Cap
- $2.6B
- Open
- $178.48
- Day Range
- $171.19 – $179.95
- Volume
- 197,108
- Prev Close
- $175.92
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.39 |
| Cost of Equity (CAPM) | 6.84% (VRP-adj) |
| WACC | 7.27% |
| Volatility Risk Premium | -1.2pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -28.4% |
| Book / Price | 7.7% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $142.54 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $137.84 |
| Bollinger Width / SMA20 | 45.0% (drives anchor stability) |
| Net Debt | $-0.2B |
| Market Cap | $3B |
Peers used for multiples: BLLN, COGT, CORT, CYTK, GH, MIRM, SYRE, TVTX
60-Day Conviction
3%
20-Day Fair Value
≈ by Dec 8, 2026
$175.54
α +0.4%
rank 35%
conviction
26%
40-Day Fair Value
≈ by Jan 6, 2027
$179.95
α +2.9%
rank 33%
conviction
78%
60-Day Fair Value
≈ by Feb 4, 2027
$175.12
α +0.1%
rank 23%
conviction
3%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $131.30 | 14% | median 9.6× · 5 peers |
| Peer P/S | n/a | 0% | median 11.3× · 6 peers |
| Market Anchor (SMA50) | $142.54 | 52% | stability 74% (BB-width) |
| Options Expected (B-L 30d) | $176.38 | 35% | 21 strikes · skew +0.18 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $2.6B
- Employees
- 29
- List Date
- 2024-12-16
- CIK
- 0001583648
- Last Earnings
- Nov 5 before open · −3.3% vs ±9.7% expected
- Headquarters
- Wayne, PA
- Homepage
- https://www.palvellatx.com
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | 8.33% | -23.52% | -7.59% |
| Feb | -- | 49.34% | 68.99% | 59.16% |
| Mar | -- | 43.17% | -6.00% | 18.59% |
| Apr | -- | 2.92% | 6.60% | 4.76% |
| May | -- | 0.17% | -6.61% | -3.22% |
| Jun | -- | -10.34% | 35.73% | 12.69% |
| Jul | -- | 61.36% | 2.89% | 32.12% |
| Aug | -- | 48.15% | 8.39% | 28.27% |
| Sep | -- | 18.93% | -8.38% | 5.27% |
| Oct | -- | 26.27% | 10.11% | 18.19% |
| Nov | -- | 33.77% | 19.54%* | 26.66% |
| Dec | -6.47% | 10.73% | -- | 2.13% |
| Total | -6.47% | 1038.48% | 120.78% | 384.26% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $139.86
SMA 50: $143.04
SMA 200: $128.90
Current: $174.93
EMA 12: $153.99
EMA 26: $145.75
MACD: 8.2416 | Signal: 5.0279
BULLISH
ADX (14): 32.98
TREND
+DI: 36.73
−DI: 9.87
Momentum Oscillators
RSI (14): 71.62
OVERBOUGHT
Stoch %K: 89.37
Stoch %D: 89.64
Williams %R: -8.57
Volume & Volatility
BB Upper: $174.75
BB Lower: $104.98
OVERBOUGHT
OBV: 10,817,530
Vol SMA 20: 269,935
Vol ROC: 78.35%
ATR: $9.51
True Range: $8.76
HV 20: 74.6%
HV 30: 66.5%
HV 60: 54.8%
Data Summary
Data Points: 475
Last Updated:
Date Range: 2024-12-16T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before PVLA’s Nov 5 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report - PVLA
Executive Summary
Overall Assessment: BULLISH (Confidence Level: 8/10)
Key Drivers:
- Strong technical momentum, with multiple indicators pointing to an ongoing uptrend
- Positive news sentiment, driven by recent clinical trial results and funding announcements
- High institutional interest, reflected in the options market's pricing of a significant move
Primary Risks:
- High volatility, which may lead to increased price swings
- Potential for mean reversion, if the stock becomes overbought or oversold
Investment Thesis:
PVLA is poised for continued growth, driven by its pipeline of innovative treatments and strong institutional support. The recent clinical trial results have generated significant excitement, and the company's funding announcements suggest a robust capital structure to fuel future development.
Recent News Sentiment Impact:
The positive news sentiment has been a key driver of PVLA's recent price appreciation. The headlines highlight the company's progress in its pipeline and its ability to attract capital, which should support future growth.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Uptrend
- Medium-term (1-3 months): Uptrend
- Long-term (3-12 months): Bullish trend potential
Support/Resistance Levels:
- Upper Bollinger Band: $164.76
- Middle Line (EMA 50): $147.37
- Lower Bollinger Band: $129.98
Momentum Signals:
- RSI interpretation: Neutral (57.39)
- MACD signal: Bullish momentum
- Bollinger Bands position: Squeeze
Volume Analysis:
- Volume SMA 20: 192319.65
- On-Balance Volume (OBV): 11071796.40
- Volume Rate of Change: -45.28%
News & Sentiment Analysis
Recent Headlines Summary:
The recent news headlines highlight the company's clinical trial results, funding announcements, and product launches. These events have driven positive sentiment and contributed to PVLA's price appreciation.
Sentiment Assessment:
Aggregate sentiment is POSITIVE (6/7 articles)
Catalyst Identification:
- Upcoming events: Earnings announcement, potential product launch
- Regulatory changes: FDA approval for QTORIN™ rapamycin
Risk & Volatility Assessment
Beta Interpretation:
Beta >1.5 indicates high risk relative to the market
Volatility Regime:
Current volatility is higher than historical levels (116.8% vs 90.5%)
Options Market Signals:
- IV rank: Low (0.0%)
- Put/call ratios: Neutral (1.29)
- Unusual activity: None noted
Market Context & Positioning
Sector Performance:
PVLA is outperforming the broader healthcare sector (0.24 correlation)
Institutional Activity:
Volume patterns suggest institutional interest, with a strong bias towards buying
Correlation Analysis:
R-squared interpretation suggests PVLA moves independently of the market
Relative Valuation:
PVLA is positioned within its trading range, with potential for further growth
Key Levels & Action Items
Critical Price Levels:
- Support: $147.37 (SMA 50), $129.98 (Lower Bollinger Band)
- Resistance: $164.76 (Upper Bollinger Band)
Breakout/Breakdown Levels:
- Breakout: Above $164.76
- Breakdown: Below $129.98
Time-Sensitive Catalysts:
- Earnings announcement: TBA
- Product launch: Potential catalyst
Risk Management:
Stop-loss levels: Consider setting stops around $147.37 and $129.98 to manage risk
Generated
News
All PVLA news →
QTORIN rapamycin wins priority FDA review for a rare vascular disease.
Earnings History
5 of 6 under expected move
Avg Expected Move
13.15%
Avg Actual Move
5.19%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2025-05-15 | Pre-Market | 23.04% | 0.41% | 0.02x | Within |
| 2025-08-14 | Pre-Market | 11.31% | 3.27% | 0.29x | Within |
| 2025-11-10 | Pre-Market | 12.33% | 3.16% | 0.26x | Within |
| 2026-05-07 | Pre-Market | 10.06% | 12.99% | 1.29x | Exceeded |
| 2026-08-04 | Pre-Market | 12.43% | 7.96% | 0.64x | Within |
| 2026-11-05 | Pre-Market | 9.71% | 3.35% | 0.35x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
PVLA Options Activity & IV Rank
PVLA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 51.3%
7-DTE IV: 58.3%
Expected Move: $22.85
7-DTE Move: $14.15
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 1,688
Put Volume: 323
P/C Volume: 0.191
BULLISH
Call OI: 1,193
Put OI: 187
P/C OI: 0.157
Total OI: 1,380
ATM Options Pricing
ATM Call: $11.65
ATM Put: $11.20
Call %: 6.7%
Put %: 6.4%
Chain Summary
Chain Volume: 2,011
Chain OI: 1,380
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 79th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
79%
vs own history
GEX tilt
+0.81
OI-weighted, today
Vanna tilt
-0.85
δ-sensitivity to IV
Charm tilt
+0.84
δ-decay vs time
Vanna tilt -0.85: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.84: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 12 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)30.3MediumNov 9
IV Rank (30 DTE)10.2LowNov 9
Straddle Price (30 DTE)$22.85Nov 9
Beta Analysis
Risk Metrics
Beta: 1.6379
Alpha: 95.24%
Correlation: 0.2663
R-Squared: 7.1%
Stock Volatility: 84.7%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own PVLA
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $8.1M | #1170 of 3138 | +196.4% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $8.0M | #1750 of 3716 | -44.2% | 13F | |
| Citadel Hedge fund Ken Griffin | $538K | #4390 of 6285 | -82.8% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
PVLA Institutional Ownership (13F)
Filings for 2026-06-30 · 67 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 13,461,841 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
7 filers$38.20M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $18.43M | 48.24% | 2026-06-30 |
| 2 | ORBIMED ADVISORS LLC | $6.11M | 16.00% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $4.65M | 12.16% | 2026-06-30 |
| 4 | Caption Management, LLC | $4.58M | 12.00% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $4.10M | 10.72% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $317.24K | 0.83% | 2026-09-30 |
| 7 | GROUP ONE TRADING LLC Custodian | $15.28K | 0.04% | 2026-06-30 |
5 filers$36.98M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Caption Management, LLC | $21.39M | 57.85% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $11.71M | 31.65% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $2.03M | 5.50% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $1.53M | 4.13% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $320.92K | 0.87% | 2026-06-30 |
PVLA Insider Trading (Form 4)
Latest: 2026-10-23Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-23 | Kathleen Goin | Chief Operating Officer | Mixed Sell −4,313 · Exer +4,313 |
— | $66.34 | -$502.3K | EDGAR |
| 2026-10-14 | George M Jenkins | Director | Sell (S) | −27,500 | $130.16 | -$3.58M | EDGAR |
| 2026-09-18 | Kathleen Goin | Chief Operating Officer | Mixed Sell −4,302 · Exer +4,302 |
— | $80.17 | -$620.0K | EDGAR |
| 2026-09-15 | George M Jenkins | Director | Sell (S) | −27,500 | $151.53 | -$4.17M | EDGAR |
| 2026-09-04 | Christopher P Kiritsy | Director | Mixed Exer +313 · Sell −313 |
— | $142.10 | -$9.3K | EDGAR |
| 2026-08-20 | Kathleen Goin | Chief Operating Officer | Mixed Sell −4,302 · Exer +4,302 |
— | $80.16 | -$619.9K | EDGAR |
| 2026-07-17 | Kathleen Goin | Chief Operating Officer | Mixed Exer +4,302 · Sell −4,302 |
— | $78.69 | -$607.3K | EDGAR |
| 2026-07-01 | Matthew Pauls | Director | Grant (A) | +6,000 opt | — | EDGAR | |
| 2026-06-22 | Kathleen Goin | Chief Operating Officer | Mixed Sell −4,302 · Exer +4,302 |
— | $59.42 | -$441.5K | EDGAR |
| 2026-06-16 | Matthew E Korenberg | CFO, Treasurer | Exer (M) | +1,000 | $13.60 | $13.6K | EDGAR |
| 2026-06-12 | George M Jenkins | Director | Grant (A) | +3,000 opt | — | EDGAR | |
| 2026-06-12 | Todd C Davis | Director | Grant (A) | +3,000 opt | — | EDGAR | |
| 2026-06-12 | Elaine J Heron | Director | Grant (A) | +3,000 opt | — | EDGAR | |
| 2026-06-12 | Christopher P Kiritsy | Director | Grant (A) | +3,000 opt | — | EDGAR | |
| 2026-06-12 | Tadd S. Wessel | Director | Grant (A) | +3,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
PVLA Insider Holdings
6 insiders · @ $174.93
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | BVF PARTNERS L P/IL | 282,223 | $49.37M | $0 | 1 | 2024-12-17 | |
| 2 | George M Jenkins | Director | 154,228 | $26.98M | -$7.04M | 9 | 2026-10-14 |
| 3 | Elaine J Heron | Director | 53,691 | $9.39M | $300.0K | 4 | 2026-06-12 |
| 4 | Kathleen Goin | Chief Operating Officer | 2,270 | $397.1K | -$6.04M | 15 | 2026-10-23 |
| 5 | Matthew E Korenberg | CFO, Treasurer | 1,000 | $174.9K | $0 | 4 | 2026-06-16 |
| 6 | Christopher P Kiritsy | Director | 250 | $43.7K | -$49.1K | 4 | 2026-09-04 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
PVLA Board & Officers
As of SEC filings through Oct 23, 2026Directors 8
- Christopher P Kiritsy · since Sep 20, 2016
- Elaine J Heron · since Dec 13, 2024
- George M Jenkins · since Dec 13, 2024
- Tadd S. Wessel · since Dec 13, 2024
- Todd C Davis · since Dec 13, 2024
- Wes Kaupinen · since Dec 13, 2024
- John Doux · since Apr 13, 2026
- Matthew Pauls · since Jun 29, 2026
Officers 5
- Wes Kaupinen · President and CEO · since Dec 13, 2024
- Matthew E Korenberg · CFO, Treasurer · since Dec 13, 2024
- Kathleen Goin · Chief Operating Officer · since Dec 13, 2024
- Jeffrey S Martini · Chief Scientific Officer · since Dec 13, 2024
- Ashley Hartmann Kline · Chief Commercial Officer · since May 27, 2025
10% owners 1
- Wes Kaupinen · since Dec 13, 2024
Changes in the last 10 years (69)
| Jun 29, 2026 | Matthew Pauls became a director |
| Apr 13, 2026 | John Doux became a director |
| May 27, 2025 | Ashley Hartmann Kline became Chief Commercial Officer |
| Feb 7, 2025 | Palvella Therapeutics, Inc. no longer listed as a director in SEC filings |
| Feb 7, 2025 | Palvella Therapeutics, Inc. first on file as a director |
| Feb 7, 2025 | Palvella Therapeutics, Inc. first on file as Chief Operating Officer |
| Dec 17, 2024 | Mark N Lampert reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2024 | Bvf Partners L P/il reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2024 | Bvf Inc/il reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2024 | Bvf I Gp LLC reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2024 | Bvf Gp Holdings LLC reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2024 | Biotechnology Value Fund L P reported in an SEC filing no longer being a 10% owner |
| Dec 16, 2024 | Dellora Investments LP reported in an SEC filing no longer being a 10% owner |
| Dec 13, 2024 | Wes Kaupinen became a director |
| Dec 13, 2024 | Wes Kaupinen became a 10% owner |
| Dec 13, 2024 | Wes Kaupinen became President and CEO |
| Dec 13, 2024 | Todd C Davis became a director |
| Dec 13, 2024 | Tadd S. Wessel became a director |
| Dec 13, 2024 | Matthew E Korenberg became CFO, Treasurer |
| Dec 13, 2024 | Kathleen Goin became Chief Operating Officer |
| Dec 13, 2024 | Jeffrey S Martini became Chief Scientific Officer |
| Dec 13, 2024 | George M Jenkins became a director |
| Dec 13, 2024 | Elaine J Heron became a director |
| Nov 6, 2024 | Dellora Investments LP became a 10% owner |
| Jul 24, 2024 | ADAR1 Partners, LP became a 10% owner |
| Jul 24, 2024 | ADAR1 Capital Management, LLC became a 10% owner |
| Jul 23, 2024 | The company announced the departure of Shane Olwill as Chief Development Officer in an SEC filing |
| Jul 13, 2023 | The company announced the departure of Ahmed Mousa as Chief Business Officer in an SEC filing |
| May 22, 2023 | Mark N Lampert first listed as a 10% owner in an SEC filing |
| May 22, 2023 | Bvf Partners L P/il first listed as a 10% owner in an SEC filing |
| May 22, 2023 | Bvf Inc/il first listed as a 10% owner in an SEC filing |
| May 22, 2023 | Biotechnology Value Fund L P first listed as a 10% owner in an SEC filing |
| May 11, 2023 | Bvf I Gp LLC became a 10% owner |
| May 11, 2023 | Bvf Gp Holdings LLC became a 10% owner |
| Aug 4, 2022 | The company announced the departure of Tim Demuth as Chief Medical Officer in an SEC filing |
| Feb 24, 2022 | Thomas Bures listed as Chief Financial Officer (previously Vice President, Finance) in SEC filings |
| Oct 6, 2021 | Ahmed Mousa became Chief Business Officer |
| Aug 1, 2021 | Tim Demuth became Chief Medical Officer |
| Aug 1, 2021 | Shane Olwill became Chief Development Officer |
| Jul 22, 2020 | Aquilo Capital Management, LLC reported in an SEC filing no longer being a 10% owner |
| Mar 12, 2020 | Aquilo Capital Management, LLC became a 10% owner |
| Sep 10, 2019 | Mark N Lampert reported in an SEC filing no longer being a 10% owner |
| Sep 10, 2019 | Mark N Lampert first listed as a 10% owner in an SEC filing |
| Sep 10, 2019 | Bvf Partners L P/il reported in an SEC filing no longer being a 10% owner |
| Sep 10, 2019 | Bvf Partners L P/il first listed as a 10% owner in an SEC filing |
| Sep 10, 2019 | Bvf Inc/il reported in an SEC filing no longer being a 10% owner |
| Sep 10, 2019 | Bvf Inc/il first listed as a 10% owner in an SEC filing |
| Sep 3, 2019 | Thomas Bures became Vice President, Finance |
| Aug 30, 2019 | Hitto Kaufmann became SVP, Chief Scientific Officer |
| Jul 31, 2019 | Maya R. Said became a director |
| Feb 1, 2019 | Mark N Lampert reported in an SEC filing no longer being a 10% owner |
| Feb 1, 2019 | Bvf Partners L P/il reported in an SEC filing no longer being a 10% owner |
| Feb 1, 2019 | Bvf Inc/il reported in an SEC filing no longer being a 10% owner |
| Nov 16, 2018 | Mark N Lampert became a 10% owner |
| Nov 16, 2018 | Bvf Partners L P/il became a 10% owner |
| Nov 16, 2018 | Bvf Inc/il became a 10% owner |
| Oct 22, 2018 | Matthew L Sherman became a director |
| Sep 7, 2018 | Peter A Kiener became a director |
| Apr 24, 2018 | Ann Barbier became a director |
| Feb 26, 2018 | Louis Matis listed as Chief Development Officer (previously SVP, Chief Development Officer) in SEC filings |
| Feb 26, 2018 | Allan Reine listed as Chief Financial Officer (previously SVP and Chief Financial Officer) in SEC filings |
| Dec 20, 2017 | Samuel D Isaly no longer listed as a director in SEC filings |
| Dec 20, 2017 | Orbimed Advisors LLC no longer listed as a director in SEC filings |
| Dec 20, 2017 | OrbiMed Capital GP III LLC no longer listed as a director in SEC filings |
| Aug 9, 2017 | Allan Reine became SVP and Chief Financial Officer |
| May 22, 2017 | James A Geraghty became a director |
| Mar 6, 2017 | Stephen S. Yoder listed as Chief Executive Officer (previously President and CEO) in SEC filings |
| Feb 2, 2017 | Lance E Thibault became Acting Chief Financial Officer |
| Nov 28, 2016 | Claude Knopf became Chief Business Officer |
Not reported recently (23)
- Palvella Therapeutics, Inc. · Last reported as Chief Operating Officer in an SEC filing dated Feb 7, 2025
- James A Geraghty · Last reported as a director in an SEC filing dated Dec 12, 2024
- Peter A Kiener · Last reported as a director in an SEC filing dated Dec 2, 2024
- ADAR1 Partners, LP · Last reported as a 10% owner in an SEC filing dated Aug 12, 2024
- ADAR1 Capital Management, LLC · Last reported as a 10% owner in an SEC filing dated Aug 12, 2024
- Michael Richman · Last reported as a director in an SEC filing dated Jun 23, 2023
- Ann Barbier · Last reported as a director in an SEC filing dated Jun 23, 2023
- Matthew L Sherman · Last reported as a director in an SEC filing dated Jun 23, 2023
- Maya R. Said · Last reported as a director in an SEC filing dated Jun 23, 2023
- Stephen S. Yoder · Last reported as a director in an SEC filing dated Jun 21, 2023
- Hitto Kaufmann · Last reported as SVP, Chief Scientific Officer in an SEC filing dated Feb 28, 2023
- Thomas Bures · Last reported as Chief Financial Officer in an SEC filing dated Feb 28, 2023
- Jean-Pierre Bizzari · Last reported as a director in an SEC filing dated Jan 28, 2020
- Louis Matis · Last reported as Chief Development Officer in an SEC filing dated Feb 28, 2019
- Allan Reine · Last reported as Chief Financial Officer in an SEC filing dated Feb 28, 2019
- Steven Prelack · Last reported as a director in an SEC filing dated Jan 29, 2019
- OrbiMed Capital GP III LLC · Last reported as a 10% owner in an SEC filing dated Feb 15, 2018
- Orbimed Advisors LLC · Last reported as a 10% owner in an SEC filing dated Feb 15, 2018
- Julian Adams · Last reported as a director in an SEC filing dated Jan 29, 2018
- Samuel D Isaly · Last reported as a 10% owner in an SEC filing dated Jan 4, 2018
- Chau Quang Khuong · Last reported as a director in an SEC filing dated Oct 27, 2017
- Lance E Thibault · Last reported as Acting Chief Financial Officer in an SEC filing dated Feb 13, 2017
- Claude Knopf · Last reported as Chief Business Officer in an SEC filing dated Nov 30, 2016
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
PVLA Proposed Insider Sales (Form 144)
Latest: 2026-10-21
? Form 144 Guide
Last 30d:
2 filings
· $4.2M notice value
· Last 90d:
5 filings
· $9.7M notice value
· 2 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
JENKINS GEORGE M (2, $7.8M) · Goin Kathleen (3, $1.8M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-21 | Goin Kathleen | Officer | 4,313 | $534.5K | 2026-10-21 | Piper Sandler & Co Inc | 10b5-1 | EDGAR |
| 2026-10-13 | JENKINS GEORGE M | Director | 27,500 | $3.70M | 2026-10-13 | Piper Sandler & Co | 10b5-1 | EDGAR |
| 2026-09-16 | Goin Kathleen | Officer | 4,302 | $650.5K | 2026-09-16 | Piper Sandler & Co Inc | 10b5-1 | EDGAR |
| 2026-09-11 | JENKINS GEORGE M | Director | 27,500 | $4.14M | 2026-09-11 | Piper Sandler | 10b5-1 | EDGAR |
| 2026-08-19 | Goin Kathleen | Officer | 4,302 | $647.1K | 2026-08-19 | Piper Sandler & Co Inc | 10b5-1 | EDGAR |
| 2026-07-15 | Goin Kathleen | Officer | 4,302 | $643.9K | 2026-07-15 | Piper Sandler & Co Inc | 10b5-1 | EDGAR |
| 2026-06-17 | Goin Kathleen | Officer | 4,302 | $476.4K | 2026-06-17 | Piper Sandler & Co Inc | 10b5-1 | EDGAR |
| 2026-05-20 | Goin Kathleen | Officer | 4,302 | $475.6K | 2026-05-20 | Piper Sandler & Co Inc | 10b5-1 | EDGAR |
| 2026-04-15 | Goin Kathleen | Officer | 4,302 | $557.2K | 2026-04-15 | Piper Sandler & Co Inc | 10b5-1 | EDGAR |
| 2026-03-18 | Goin Kathleen | Officer | 4,302 | $519.7K | 2026-03-18 | Piper Sandler and Co | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-05 | Earnings results · Regulation FD disclosure | EDGAR |
| 2026-10-28 | Other events | EDGAR |
| 2026-08-04 | Earnings results · Regulation FD disclosure | EDGAR |
| 2026-07-14 | Other events | EDGAR |
| 2026-06-30 | Director or officer change | EDGAR |
| 2026-06-16 | Director or officer change · Shareholder vote results | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
37 ETFs hold PVLA
25 shown · $240.67M total exposure · 0.06% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.59% | $58.8M | $10.0B | 2026-11-05 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.07% | $54.3M | $76.6B | 2026-11-06 |
| 3 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $53.9M | — | 2026-09-30 |
| 4 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.15% | $19.9M | $13.7B | 2026-11-06 |
| 5 | VXF Vanguard Extended Market ETF | Vanguard | 0.02% | $19.1M | — | 2026-09-30 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.05% | $9.5M | — | 2026-09-30 |
| 7 | VHT Vanguard Health Care ETF | Vanguard | 0.02% | $4.4M | — | 2026-09-30 |
| 8 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $3.0M | $93.2B | 2026-11-06 |
| 9 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.16% | $2.8M | — | 2026-11-05 |
| 10 | LFSC F/m Emerald Life Sciences Innovation ETF | Nport | 2.15% | $2.7M | — | 2026-08-31 |
| 11 | SBIO ALPS Medical Breakthroughs ETF | Nport | 1.12% | $2.7M | — | 2026-08-31 |
| 12 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.41% | $2.1M | — | 2026-11-06 |
| 13 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.11% | $1.8M | — | 2026-09-30 |
| 14 | RSSL Global X Russell 2000 ETF | Global X | 0.07% | $1.0M | — | 2026-11-06 |
| 15 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.09% | $892,476 | $1.0B | 2026-11-05 |
| 16 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.02% | $870,204 | $4.0B | 2026-11-05 |
| 17 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $614,313 | $19.7B | 2026-11-06 |
| 18 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.01% | $613,754 | $10.0B | 2026-11-05 |
| 19 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.01% | $502,704 | $6.6B | 2026-11-05 |
| 20 | BBC Virtus Biotech Clinical Trials Etf | Nport | 0.86% | $397,098 | — | 2026-07-31 |
| 21 | ISCG iShares Morningstar Small-Cap Growth ETF | iShares (BlackRock) | 0.03% | $281,120 | $934.3M | 2026-11-06 |
| 22 | ISCV iShares Morningstar Small-Cap Value ETF | iShares (BlackRock) | 0.03% | $183,485 | $685.4M | 2026-11-06 |
| 23 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $143,033 | — | 2026-09-30 |
| 24 | WSML iShares MSCI World Small-Cap ETF | iShares (BlackRock) | 0.02% | $120,857 | $656.6M | 2026-11-06 |
| 25 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.07% | $118,218 | — | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-5.49
TTM Revenue
$0.00
TTM Net Income
$-74.99M
TTM Op. Cash Flow
$-43.06M
Quarterly figures (8 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $0.00 | $-24.64M | $-1.70 | $-14.43M |
| Q2 '26 | 2026-06-30 | — | $-21.87M | $-1.52 | $-12.85M |
| Q1 '26 | 2026-03-31 | — | $-15.77M | $-1.20 | $-10.86M |
| Q4 '25 | 2025-12-31 | — | $-12.71M | $-1.08 | $-4.93M |
| Q3 '25 | 2025-09-30 | $0.00 | $-11.35M | $-1.03 | $-7.88M |
| Q2 '25 | 2025-06-30 | — | $-9.47M | $-0.86 | $-5.43M |
| Q1 '25 | 2025-03-31 | — | $-8.19M | $-0.74 | $-6.77M |
| Q4 '24 | 2024-12-31 | — | $-3.37M | $0.12 | $-5.39M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
10.03
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-28.4%
ROA
-24.3%
Div Yield
0.00%
FCF Yield
-1.68%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$2.18B
as of 2026-11-09
PVLA vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| GH Guardant Health, Inc. Common Stock | $20.4B | — | +42.7% | +57.5% | 25 |
| SYRE Spyre Therapeutics, Inc. Common Stock | $9.9B | — | — | +258.8% | 9 |
| CORT Corcept Therapeutics Inc. | $7.9B | 59.0 | +30.0% | +96.1% | 100 |
| CYTK Cytokinetics Inc. | $7.5B | — | −21.1% | −10.2% | 53 |
| MIRM Mirum Pharmaceuticals, Inc. Common Stock | $6.1B | — | +42.2% | +18.9% | 36 |
| COGT Cogent Biosciences, Inc. Common Stock | $5.5B | — | — | −3.0% | 100 |
| BLLN BillionToOne, Inc. Class A Common Stock | $5.4B | 165.1 | — | +29.5% | 47 |
| TVTX Travere Therapeutics, Inc. Common Stock | $4.8B | — | +49.4% | +29.0% | 21 |
| PVLA Palvella Therapeutics, Inc. Common Stock | $2.6B | — | — | +74.4% | 10 |
| Peer median | $6.8B | 112.0 | +42.2% | +29.2% | 42 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
2.41M
SI % of Float
21.73%
Days to Cover
9.83
Short Vol Ratio
66.8%
Free Float
11.08M
Float %
76.9%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-24